BASF Pharma 20% Price Hike on Excipients and APIs Hits Global Drug Supply Chain

On March 30, 2026, BASF Pharma Solutions announced a global price increase of up to 20% on its entire portfolio of pharmaceutical excipients and selected active pharmaceutical ingredients (APIs). The adjustment took immediate effect or will apply as existing contracts allow. BASF cited rising global energy costs and raw material prices as the primary drivers behind the decision.

BASF SE, headquartered in Ludwigshafen, Germany, is the world largest chemical company and operates the biggest portfolio of chemical raw materials for the pharmaceutical industry. Its Pharma Solutions division supplies critical inactive ingredients and active compounds used in thousands of medications worldwide. The scale of this price adjustment is significant because BASF excipients and APIs are deeply embedded in global pharmaceutical manufacturing.

The price hike covers two main product categories. The first is excipients, which are inactive ingredients essential to drug formulations. BASF produces widely used excipient families including Kollidon (povidone, copovidone, and crospovidone), Kollicoat (coating polymers), Kolliphor (solubilizers and emulsifiers), Soluplus (solubilization polymer), and polyethylene glycols (PEGs). These materials serve as binders, disintegrants, coatings, and solubilizers in virtually all oral solid dosage forms such as tablets and capsules.

The second category includes selected APIs. BASF is the world leading manufacturer of ibuprofen, produced at its major facility in Bishop, Texas, which has been operational since 1992. The company also supplies omega-3 fatty acid ethyl esters, L-menthol, PVP-iodine (used in Betadine antiseptic products), azelaic acid, and dexpanthenol.

The downstream impact on common medications is extensive. On the API side, ibuprofen is one of the most consumed pain relievers globally. It is the active ingredient in widely recognized brands such as Advil, Nurofen, Motrin, and Brufen, along with hundreds of generic versions sold in virtually every country. As the dominant global producer of ibuprofen API, any BASF price movement directly affects the cost structure of these products for manufacturers worldwide.

On the excipient side, the impact is even broader. Povidone and crospovidone, sold by BASF under the Kollidon brand, are among the most commonly used pharmaceutical excipients in the world. Crospovidone functions as a super-disintegrant that allows tablets to break apart quickly after ingestion, enabling the body to absorb the active ingredient. Povidone serves as a binder that holds tablet formulations together. These two materials appear in the ingredient lists of an enormous range of everyday medications including acetaminophen (Tylenol, Doliprane, Panadol), blood pressure medications, cholesterol-lowering statins, oral diabetes drugs, common antibiotics in tablet form, and antidepressants.

Kolliphor EL, formerly known as Cremophor EL, is another critical BASF excipient affected by this increase. It is used as a solubilizer in injectable formulations for several important drugs including paclitaxel (marketed as Taxol for cancer treatment), cyclosporine (Sandimmune, an immunosuppressant), miconazole (antifungal), nelfinavir (HIV protease inhibitor), and vitamin K injections. Any cost increase on Kolliphor EL could affect pricing across oncology, transplant medicine, and critical care settings.

This price adjustment does not exist in isolation. It is part of a broader pattern of cost increases across BASF product lines in early 2026. In mid-March 2026, BASF had already announced price hikes of up to 30% on products in its Home Care and Industrial and Institutional Cleaning division across Europe. On April 1, 2026, additional increases of up to 30% took effect on selected products in the Home Care, Industrial Cleaning, and Industrial Formulators portfolios across North and South America.

The underlying cause is linked to the ongoing geopolitical crisis centered on the Strait of Hormuz, which has disrupted global energy markets and driven up costs for petrochemical feedstocks, transportation, and manufacturing. BASF, as one of the largest consumers of energy and petrochemical raw materials in the world, is particularly exposed to these cost pressures. The company Verbund production model, which integrates chemical production processes at large-scale sites like Ludwigshafen, relies heavily on stable energy inputs.

For the pharmaceutical industry, BASF price increases create a ripple effect. Drug manufacturers who rely on BASF excipients and APIs face higher input costs that may ultimately be passed along to wholesalers, pharmacies, and patients. Generic drug makers operating on thin margins are especially vulnerable, as excipients can represent a meaningful share of their production costs. The timing is particularly challenging because several major pharmaceutical companies were already navigating supply chain disruptions related to Middle East shipping route changes and elevated logistics costs.

BASF stated that it will continue to monitor market conditions and communicate any further adjustments as needed. The company framed the increase as necessary to maintain reliable supply of high-quality pharmaceutical products. However, the open-ended nature of the announcement, with no fixed end date or cap beyond the stated 20%, creates ongoing uncertainty for buyers and formulators who depend on BASF materials.

The pharmaceutical excipients market is valued at approximately 9 to 10 billion USD globally, and BASF holds one of the largest market shares in this space. A 20% price increase from the market leader has the potential to trigger similar moves from competing excipient suppliers, amplifying the cost impact across the entire industry. Companies such as Ashland, Evonik, and Merck (Sigma-Aldrich) also supply pharmaceutical excipients, but switching suppliers for regulated pharmaceutical products is a complex and time-consuming process that requires stability testing and regulatory filings.

This incident highlights the concentration risk inherent in the pharmaceutical supply chain. When a single company holds dominant positions in multiple critical input categories, from ibuprofen API to povidone binders to Kolliphor solubilizers, a single pricing decision can cascade across therapeutic areas ranging from over-the-counter pain relief to cancer chemotherapy.